Nice.
Gives some comfort, outside of the good work done HC people, especially the confidence around submission to FDA.
The change in language from 3rdQTR to "after the half year" hit me in the face...but maybe I'm a bit sensitive to this delay/no delay issue.
In the end they will submit and a little leeway won't change anything.
The interaction with the FDA on the pathway sounds really positive and I keep hearing the CEO's words around not if but when the device will be approved.
Never comfortable but remain very confident we'll at least get approved. Worry about the commercialisation after that.
Nice.Gives some comfort, outside of the good work done HC...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EBR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
-0.020(1.77%) |
Mkt cap ! $342.0M | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.14 | $1.08 | $107.6K | 97.68K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4124 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.12 | 4000 | 2 |
View Market Depth
| Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
| EBR (ASX) Chart |